ReviewJournal of current ophthalmology
An Update on Anti-Vascular Endothelial Growth Factor Treatment for Retinopathy of Prematurity.
Review in Journal of current ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Laser Speckle Flowgraphy Assessment of Ocular Blood Flow in School-Aged Children With or Without a History of Retinopathy of Prematurity.Clinical & experimental ophthalmology · 2026Observational
- Assessment of anti-VEGF intravitreal injection effects on murine neonatal Schlemm's canal morphology.Scientific reports · 2026Article
- Retinopathy of Prematurity: Historical Evolution of Clinical Management and Medico-Legal Evaluation in Japan.Healthcare (Basel, Switzerland) · 2026Review
- Evaluation of regression, reactivation, retreatment and retinal detachment after injections of three different anti-VEGF drugs for retinopathy of prematurity.Scientific reports · 2026Article
- Short-Term Efficacy of Two-Step Treatment of Retinopathy of Prematurity in a Japanese Cohort: Anti-VEGF Therapy Followed by Routine Laser Photocoagulation.Journal of clinical medicine · 2025Article
- Beyond anti-VEGF: expanding the therapeutic horizon and biomarker landscape in retinopathy of prematurity.Frontiers in pediatrics · 2025Review
- Comparison of ranibizumab and conbercept treatment in type 1 prethreshold retinopathy of prematurity in zone II.BMC pediatrics · 2024Article
- A promising case of preclinical-clinical translation: β-adrenoceptor blockade from the oxygen-induced retinopathy model to retinopathy of prematurity.Frontiers in physiology · 2024Review
- A review on retinopathy of prematurity.Medical hypothesis, discovery & innovation ophthalmology journal · 2024Review
- Persistent avascular retina in eyes with retinopathy of prematurity: A comprehensive review.Taiwan journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To present updated information on the role of anti-vascular endothelial growth factor (anti-VEGF) therapy for treating retinopathy of prematurity (ROP). Methods: We searched through PubMed and Scopus databases using the keywords of this article and gathered relevant published articles from the year 2005 to December 2022. The selected articles were classified and summarized, and reasonable conclusions were made accordingly. Results: Considering the current evidence, anti-VEGF agents are superior to laser therapy for the initial treatment of type 1 ROP in zone 1 or posterior zone 2. However, there is a substantial risk of reactivation or persistent avascular retina after solo treatment with anti-VEGFs, and many cases may require laser therapy within the following weeks or months. Thus, vigilant follow-up examinations are mandatory. Conclusions: The role of anti-VEGF agents in the treatment of ROP is indispensable. However, future studies are required to improve indications and dosage and determine long-term ocular and systemic safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.